Cargando…

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Husain Yar, Ge, James, Nagasaka, Misako, Aboukameel, Amro, Mpilla, Gabriel, Muqbil, Irfana, Szlaczky, Mark, Chaker, Mahmoud, Baloglu, Erkan, Landesman, Yosef, Mohammad, Ramzi M., Azmi, Asfar S., Sukari, Ammar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982268/ https://www.ncbi.nlm.nih.gov/pubmed/31905765 http://dx.doi.org/10.3390/ijms21010237

Ejemplares similares

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
por: Mpilla, Gabriel, et al.
Publicado: (2019)

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
por: Muqbil, Irfana, et al.
Publicado: (2019)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma
por: Khan, Husain Yar, et al.
Publicado: (2021)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth
por: Khan, Husain Yar, et al.
Publicado: (2020)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Nuclear Export Inhibition for Pancreatic Cancer Therapy
por: Muqbil, Irfana, et al.
Publicado: (2018)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
por: Rane, Chetan, et al.
Publicado: (2017)

Cancer cachexia research: coming of age
por: Muqbil, Irfana, et al.
Publicado: (2023)

Ouabain Effects on Human Anaplastic Thyroid Carcinoma 8505C Cells
por: Teixeira, Mariana Pires, et al.
Publicado: (2022)

Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
por: Muqbil, Irfana, et al.
Publicado: (2011)

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma
por: Diab, Maria, et al.
Publicado: (2016)

Curcumin Enhances Docetaxel-Induced Apoptosis of 8505C Anaplastic Thyroid Carcinoma Cells
por: Hong, Jung Min, et al.
Publicado: (2014)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

Berberine Inhibited the Growth of Thyroid Cancer Cell Lines 8505C and TPC1
por: Park, Kyoung Sik, et al.
Publicado: (2012)

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer
por: Gao, Jiankun, et al.
Publicado: (2014)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways
por: Park, Chan Ho, et al.
Publicado: (2018)

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
por: Al-Katib, Ayad M, et al.
Publicado: (2009)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis
por: Muqbil, Irfana, et al.
Publicado: (2020)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Connecting the Human Microbiome and Pancreatic Cancer
por: Sexton, Rachel E., et al.
Publicado: (2022)

Correction to: Connecting the human microbiome and pancreatic cancer
por: Sexton, Rachel E., et al.
Publicado: (2022)

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
por: Mohammad, Ramzi M, et al.
Publicado: (2009)

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization
por: Wrobel, Kinga, et al.
Publicado: (2016)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
por: Fisher, Jack G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ariubq8urbm2nueol7bjqvoe42